Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) finished Thursday with an addition of $0.42 to close at $6.54, an upside of 6.86 percent. An average of 1,450,420 shares of common stock have been traded in the last five days. There was a gain of $1.24 in the past week. The last 20 days have seen an average of 1,072,965 shares traded, while the 50-day average volume stands at 885,540.
CPRX stock has increased by 29.25% in the last month. The company shares reached their 1-month lowest point of $4.81 on 09/20/21. With the stock rallying to its 52-week high on 10/07/21, shares of the company touched a low of $2.88 and a high of $6.24 in 52 weeks. In spite of this, the price is up 4.89% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
43 days have passed since Catalyst Pharmaceuticals Inc. (CPRX) last reported insider trading activity. COELHO PHILIP H, who is Director, most recently acquired $9,548 shares at $5.45 per share on Aug 26. In this transaction, the insider spent $52,042. Chief Operating Officer, Miller Steve, disposed of 80,000 shares at a price of $5.56 on Aug 25. The insider now owns more than $444,640 worth of shares. Prior to that, Director COELHO PHILIP H went on to Sale 9,498 shares at $5.56 each on Aug 25. An amount of $52,809 was transacted.
Catalyst Pharmaceuticals Inc. (CPRX) has a trailing price-to-earnings (P/E) ratio of 9.33, which compares with the 34.65 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. In the last five years, Catalyst Pharmaceuticals Inc.’s PE ratio has ranged between 71.25 and 4.433. The stock’s beta is 1.35. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 5.40, the price-to-book (PB) ratio at 3.57.
The quick ratio of Catalyst Pharmaceuticals Inc. for the three months ended June 29 was 10.50, and the current ratio was 10.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 For the recent quarter ending June 29. Catalyst Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is 35.43%, while its operating margin for the same period stands at 36.20%. Its gross profit as reported stood at $102.03 million compared to revenue of $119.07 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Catalyst Pharmaceuticals Inc.’s return on assets was 38.60%, compared to -5.0% over the last five years. In the past year, the return on investment has been 43.90%, and the 5-year average is -3.3%. Meanwhile, the return on equity (ROE) for the past 12 months has been 43.00% and the 5-year average holds at -3.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Catalyst Pharmaceuticals Inc. had $19.98 million in cash. The analyst consensus anticipated Catalyst Pharmaceuticals Inc.’s latest quarter earnings to come in at $0.1 per share, but it turned out to be $0.11, a 10.00% surprise. For the recent quarter, EBITDA amounted to $15.87 million. Shareholders own equity worth $102.98 million.
From a technical analysis perspective, let’s take a brief look at Catalyst Pharmaceuticals Inc. (CPRX) price momentum. RSI 9-day as of the close on 07 October was 85.25%, suggesting the stock is Overbought, with historical volatility in this time frame at 57.57%.
As of today, CPRX’s price is $5.75 +23.40% or $1.24 from its 5-day moving average. CPRX is currently trading +29.25% higher than its 20-day SMA and +19.13% higher than its 100-day SMA. However, the stock’s current price level is +11.04% above the SMA50 and +86.32% above the SMA200.
The stochastic %K and %D were 92.52% and 78.03%, respectively, and the average true range (ATR) was 0.33. With the 14-day stochastic at 96.65% and the average true range at 0.29, the RSI (14) stands at 77.64%. The stock has reached 0.59 on the 9-day MACD Oscillator while the 14-day reading was at 0.78.
Cantor Fitzgerald launched coverage on Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) in its analyst report released on September 21, 2018. The firm assigned the stock a an Overweight rating.The consensus rating for Catalyst Pharmaceuticals Inc. (CPRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell CPRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is CPRX’s price target for the next 12 months?
Analysts predict a range of price targets between $6.50 and $11.00, with a median target of $8.00. Taking a look at these predictions, the average price target given by analysts for Catalyst Pharmaceuticals Inc. (CPRX) stock is $8.50.